Journal of Dali University ›› 2021, Vol. 6 ›› Issue (2): 46-50.DOI: 10. 3969 / j. issn. 2096-2266. 2021. 02. 009
Previous Articles Next Articles
Suo Guangxi, Hu Changxiao, Xiao Tianbao*
Received:
Revised:
Online:
Published:
Abstract: Objective: To study the mechanism of Tongxie-Yaofang in treating inflammatory bowel disease using network pharmacology. Methods: Effective chemical compositions and targets of drugs in Tongxie-Yaofang was searched in the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform(TCMSP). Then the targets of IBD were obtained through GeneCards and OMIM databases, the R software was used to find the common target and a "pharmaceutical component-disease target" network was constructed by means of Cytoscape software. Finally, a common target protein interaction network was constructed through the STRING website, core targets were screened out and the mechanism of its action was explored through GO analysis and KEGG pathway enrichment analysis. Results: The study has found 39 effective pharmaceutical ingredients and 125 biological targets. Among the 104 targets that coincide with the disease, the core targets are IL6, AKT1, MAPK3, JUN, CASP3, and MAPK1, etc. The molecular functions involved in GO analysis are mainly amide binding, nuclear receptor activity, transcription factor activity, phosphatase binding, and steroid hormone receptor activity. KEGG pathway enrichment analysis is mainly for TNF signaling pathway, IL-17 signaling pathway, Toll-like receptor signaling pathway etc. Conclusion: Tongxie-Yaofang is used to treat inflammatory bowel disease through "multicomponents, multi-targets, and multi-pathways", which lays a foundation for the next step of experimental verification and new drug development.
Key words: Tongxie-Yaofang, network pharmacology, inflammatory bowel disease, target, mechanism
CLC Number:
R285
Suo Guangxi, Hu Changxiao, Xiao Tianbao. The Mechanism of Tongxie-Yaofang in Treating Inflammatory Bowel Disease Based on#br# Network Pharmacology[J]. Journal of Dali University, 2021, 6(2): 46-50.
0 / / Recommend
Add to citation manager EndNote|Ris|BibTeX
URL: http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/10. 3969 / j. issn. 2096-2266. 2021. 02. 009
http://journal15.magtechjournal.com/Jwk_dlxyzk/EN/Y2021/V6/I2/46
1055.
〔7〕崔国宁,刘喜平,曾庆涛. 痛泻要方治疗溃疡性结肠炎机 制初探〔J〕. 中国民族民间医药,2017,26(7):4-5. 〔8〕冯思敏,宁可,邵平,等. β-谷甾醇和豆甾醇对小鼠急性 结肠炎的治疗作用研究〔J〕. 中国粮油学报,2018,33 (12):80-86. 〔9〕刘琦,罗霞,罗爽,等. 芍药苷通过抑制NLRP3炎症小体 治疗溃疡性结肠炎小鼠的研究〔J〕. 中药新药与临床药 理,2018,29(4):409-414. 〔10〕张旖晴,魏玮,苏晓兰,等. 中药有效成分在溃疡性结肠 炎相关信号转导通路中的作用研究进展〔J〕. 医学综 述,2020,26(4):743-747. 〔11〕郭军雄,闫立国. 痛泻要方及防风对肝郁脾虚型溃疡性 结肠炎大鼠结肠黏膜COX-2 及外周血中IL-6 的影 响〔J〕. 中医研究,2017,30(11):73-77. 〔12〕黎莉,杨卫文,谭松,等. 溃疡性结肠炎患者外周血及结 肠黏膜TNF-a、IL-6和IL-2变化的临床意义〔J〕. 中国 现代医学杂志,2016,26(14):42-47. 〔13〕伏代刚,黄晓丽,甘华田,等. PTEN/PI3K/AKT在溃疡性 结肠炎炎症-肿瘤序列演进中的作用〔J〕. 四川大学学 报(医学版),2009,40(6):1021-1023. 〔14〕顾培青,沈洪,朱磊,等. 清肠化湿方对TNBS大鼠结肠 组织PPAR-γ/p38 MAPK 的影响〔J〕. 山东中医药大学 学报,2017,41(1):81-85. 〔15〕郑娟红,陈怡. 重症溃疡性结肠炎患者血清NOD样受 体蛋白3、半胱氨酸天冬氨酸特异性蛋白酶1和核因子 κB mRNA表达水平及临床意义〔J〕. 中华危重症医学杂 志(电子版),2019,12(1):31-36. 〔16〕宋颖. 溃疡性结肠炎外周血SOCS-3、TNF-α、NO水平 与肠道菌群多样性关系〔J〕. 热带医学杂志,2016,16 (10):1283-1285. 〔17〕蔡清红,马松炎,钟俊锋. 炎症性肠病患者CXCR1、IL- 17的表达及其意义〔J〕. 中国医药导报,2019,16(32): 99-102. 〔18〕张颖慧,董向前,白丽萍,等. Toll样受体、前列腺素受 体EP2在溃疡性结肠炎组织的表达与炎症细胞因子的 关系〔J〕. 四川医学,2019,40(4):390-394.